Abcam Launches SimpleStep ELISA Kits
![](/46/pdcnewsitem/03/25/76/k4l6HqPvJpi0dQ1.jpg)
Abcam plc., a producer and distributor of high quality protein research tools, has launched a range of SimpleStep ELISA kits. The new kits have a greatly simplified protocol when compared with standard multi-step ELISAs, providing significant time savings and ease of use.
Offering enhanced performance, SimpleStep ELISA kits are single wash, colorimetric sandwich ELISAs that retain the familiar process and data outputs of a traditional ELISA kit. The kits require no specialised training or instrumentation and in contrast to standard ELISA achieve increased accuracy due to reduced sample handling steps. In addition, a more efficient in-solution binding process provides superior sensitivity and specificity.
The SimpleStep kits are ideal for studying intra- or extra- cellular signaling pathways or for cancer biomarker research. Numerous new kits are being added to the already extensive range each month. The kits are available in convenient off-the-shelf 1, 2, or 4 target conformation. Custom multi-target kits are also available, allowing customers to select analyte combinations specific to their research.
James Murray, General Manager, Abcam Eugene, commented: “Abcam is continually in touch with researchers to anticipate the latest research trends and developments, so that we can continue to meet their needs worldwide. We’re excited to see how SimpleStep ELISA kits will help to increase the pace of scientific discoveries.”
Developed and manufactured at Abcam’s laboratories, SimpleStep ELISAs have been extensively validated for specificity and sensitivity in a broad range of sample types and are accompanied by information-rich datasheets and expert scientific support. Addition of these kits enhances Abcam’s already extensive immunoassay portfolio consisting of 1600 products for the detection of more than 600 targets.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance